Efficacy Of Osimertinib In Afatinib-Resistant Lung Cancer Harboring Uncommon Egfr Mutations: Case Report And Literature Review

Afatinib remains the only drug approved by the United States Food and Drug Administration for non-small-cell lung cancer with uncommon epithelial growth factor receptor (EGFR) mutations, especially for those harboring G719X, L861G, and S768I mutations. However, it remains elusive how to manage these patients after they develop afatinib resistance.Here, we report a patient with advanced non-small-cell lung cancer harboring a rare EGFR G719A/R776C compound mutations. The patient achieved excellent anti-tumor response to osimertinib after the failure of afatinib.Our case provides a potential effective strategy after development of afatinib resistance among patients harboring uncommon EGFR mutations.